环磷酰胺减轻非icans神经毒性后，西他他烯自己醇治疗。

IF 21 1区医学 Q1 HEMATOLOGY

Blood Pub Date : 2025-06-05 DOI:10.1182/blood.2024028172

Viktoria Blumenberg, Benjamin R Puliafito, Charlotte E Graham, Mark B Leick, Md Raihan Chowdhury, Maxx King, Deshea L Harris, Noopur S Raje, Andrew R Branagan, Andrew J Yee, Diana Cirstea, Kathleen M E Gallagher, Jörg Dietrich, Marcela V Maus, Matthew J Frigault

{"title":"环磷酰胺减轻非icans神经毒性后，西他他烯自己醇治疗。","authors":"Viktoria Blumenberg, Benjamin R Puliafito, Charlotte E Graham, Mark B Leick, Md Raihan Chowdhury, Maxx King, Deshea L Harris, Noopur S Raje, Andrew R Branagan, Andrew J Yee, Diana Cirstea, Kathleen M E Gallagher, Jörg Dietrich, Marcela V Maus, Matthew J Frigault","doi":"10.1182/blood.2024028172","DOIUrl":null,"url":null,"abstract":"Abstract: Potentially fatal non-immune effector cell-associated neurotoxicity syndrome neurotoxicities (NINTs) after B-cell maturation antigen-targeted chimeric antigen receptor (CAR) T-cell therapy have been linked to high CAR T-cell expansion. Cyclophosphamide to ablate CAR T cells is an effective strategy to mitigate steroid-refractory NINTs.","PeriodicalId":9102,"journal":{"name":"Blood","volume":" ","pages":"2788-2793"},"PeriodicalIF":21.0000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment.\",\"authors\":\"Viktoria Blumenberg, Benjamin R Puliafito, Charlotte E Graham, Mark B Leick, Md Raihan Chowdhury, Maxx King, Deshea L Harris, Noopur S Raje, Andrew R Branagan, Andrew J Yee, Diana Cirstea, Kathleen M E Gallagher, Jörg Dietrich, Marcela V Maus, Matthew J Frigault\",\"doi\":\"10.1182/blood.2024028172\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract: Potentially fatal non-immune effector cell-associated neurotoxicity syndrome neurotoxicities (NINTs) after B-cell maturation antigen-targeted chimeric antigen receptor (CAR) T-cell therapy have been linked to high CAR T-cell expansion. Cyclophosphamide to ablate CAR T cells is an effective strategy to mitigate steroid-refractory NINTs.\",\"PeriodicalId\":9102,\"journal\":{\"name\":\"Blood\",\"volume\":\" \",\"pages\":\"2788-2793\"},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2025-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1182/blood.2024028172\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/blood.2024028172","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

bcma靶向CAR -t细胞治疗后潜在致命的非icans神经毒性（NINTs）与CAR -t细胞的高扩增和持续时间延长有关。环磷酰胺消融CAR - t细胞是缓解NINTs类固醇难治性病程的有效治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment.

Abstract: Potentially fatal non-immune effector cell-associated neurotoxicity syndrome neurotoxicities (NINTs) after B-cell maturation antigen-targeted chimeric antigen receptor (CAR) T-cell therapy have been linked to high CAR T-cell expansion. Cyclophosphamide to ablate CAR T cells is an effective strategy to mitigate steroid-refractory NINTs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Blood 医学-血液学

CiteScore

23.60

自引率

3.90%

发文量

955

审稿时长

1 months

期刊介绍： Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy scope; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate.